← Back to all trials
Not Yet Recruiting
NCT07813572
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
Conditions: Hepatocellular Carcinoma
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 600
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Location: Nanjing Tianyinshan Hospital Nanjing Jiangsu
Summary
The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC
Eligibility Criteria
Inclusion Criteria:
* Participants with histologically/cytologically confirmed unresectable or metastatic advanced HCC;
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
* Barcelona Clinic Liver Cancer stage B, not suitable for local treatment and BCLC C.
* At least one measurable lesion based on Recist1.1.
* No prior systemic therapy for HCC.
* Child-Pugh ≤6 , no history of hepatic encephalopathy.
Exclusion Criteria:
* Active Central nervous system (CNS) metastasis or leptomeningeal metastases.
* Any condition that is not suitable for participate in this study as determined by investigator.
Source: ClinicalTrials.gov (NCT07813572). StuddyBuddy aggregates publicly available trial information.
